首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Defining stopping criteria for ending randomized clinical trials that investigate the interruption of transmission of soil-transmitted helminths employing mass drug administration
【2h】

Defining stopping criteria for ending randomized clinical trials that investigate the interruption of transmission of soil-transmitted helminths employing mass drug administration

机译:定义终止标准以结束通过大规模药物管理调查土壤传播蠕虫传播中断的随机临床试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The current World Health Organization strategy to address soil-transmitted helminth (STH) infections in children is based on morbidity control through routine deworming of school and pre-school aged children. However, given that transmission continues to occur as a result of persistent reservoirs of infection in untreated individuals (including adults) and in the environment, in many settings such a strategy will need to be continued for very extended periods of time, or until social, economic and environmental conditions result in interruption of transmission. As a result, there is currently much discussion surrounding the possibility of accelerating the interruption of transmission using alternative strategies of mass drug administration (MDA). However, the feasibility of achieving transmission interruption using MDA remains uncertain due to challenges in sustaining high MDA coverage levels across entire communities. The DeWorm3 trial, designed to test the feasibility of interrupting STH transmission, is currently ongoing. In DeWorm3, three years of high treatment coverage—indicated by mathematical models as necessary for breaking transmission—will be followed by two years of surveillance. Given the fast reinfection (bounce-back) rates of STH, a two year no treatment period is regarded as adequate to assess whether bounce-back or transmission interruption have occurred in a given location. In this study, we investigate if criteria to determine whether transmission interruption is unlikely can be defined at earlier timepoints. A stochastic, individual-based simulation model is employed to simulate core aspects of the DeWorm3 community-based cluster-randomized trial. This trial compares a control arm (annual treatment of children alone with MDA) with an intervention arm (community-wide biannual treatment with MDA). Simulations were run for each scenario for both Ascaris lumbricoides and hookworm (Necator americanus). A range of threshold prevalences measured at six months after the last round of MDA and the impact of MDA coverage levels were evaluated to see if the likelihood of bounce-back or elimination could reliably be assessed at that point, rather than after two years of subsequent surveillance. The analyses suggest that all clusters should be assessed for transmission interruption after two years of surveillance, unless transmission interruption can be effectively ruled out through evidence of low treatment coverage. Models suggest a tight range of homogenous prevalence estimates following high coverage MDA across clusters which do not allow for discrimination between bounce back or transmission interruption within 24 months following cessation of MDA.
机译:世界卫生组织当前解决儿童中土壤传播的蠕虫(STH)感染的策略是基于对例行学龄和学龄前儿童的常规驱虫控制病害。但是,由于传播是由于未经治疗的个人(包括成年人)和环境中持续存在的感染源而继续发生的,因此在许多情况下,这种策略将需要持续很长时间,或者直到社会出现,经济和环境条件导致传输中断。结果,当前有大量讨论围绕使用大规模药物管理(MDA)的替代策略加速传播中断的可能性。但是,由于在整个社区维持较高的MDA覆盖率方面存在挑战,因此使用MDA实现传输中断的可行性仍然不确定。目前正在进行DeWorm3试验,旨在测试中断STH传输的可行性。在DeWorm3中,三年的高治疗覆盖率-由打破传播所必需的数学模型表示-随后将进行两年的监视。鉴于STH的快速再感染(反弹)率,没有两年的治疗期被认为足以评估给定位置是否发生了反弹或传播中断。在这项研究中,我们调查是否可以在较早的时间点确定确定是否不太可能发生传输中断的标准。基于个人的随机模拟模型用于模拟基于DeWorm3社区的集群随机试验的核心方面。该试验将对照组(单独接受MDA儿童的年度治疗)与干预组(采用MDA的全社区半年度治疗)进行了比较。针对each虫和钩虫(Necator americanus)的每种情况都进行了仿真。在最后一轮MDA之后六个月测得的一系列阈值患病率和MDA覆盖水平的影响进行了评估,以查看是否可以可靠地评估反弹或消除的可能性,而不是随后的两年监视。分析表明,除非经过低治疗覆盖率的证据可以有效地排除传播中断,否则应在监测两年后评估所有类群的传播中断。模型表明,在跨集群的高覆盖MDA之后,均一性患病率估计值范围很窄,因此无法区分MDA停止后24个月内反弹还是传播中断。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号